Details about Tom Stargardt

Access statistics for papers by Tom Stargardt.

Last updated 2018-09-25. Update your information in the RePEc Author Service.

Short-id: pst545

Working Papers

2012

1. Measuring the relationship between costs and outcomes: The example of Acute Myocardial Infarction in German hospitals
   hche Research Papers, University of Hamburg, Hamburg Center for Health Economics (hche) View citations (5)
   See also Journal Article MEASURING THE RELATIONSHIP BETWEEN COSTS AND OUTCOMES: THE EXAMPLE OF ACUTE MYOCARDIAL INFARCTION IN GERMAN HOSPITALS, Health Economics, John Wiley & Sons, Ltd. (2014) View citations (8) (2014)

2011

2. Effect of type of insurance and income on waiting time for outpatient care
   hche Research Papers, University of Hamburg, Hamburg Center for Health Economics (hche) View citations (4)
   See also Journal Article Effect of Type of Insurance and Income on Waiting Time for Outpatient Care, The Geneva Papers on Risk and Insurance - Issues and Practice, Palgrave Macmillan (2012) View citations (12) (2012)

2005

3. Defining benefit catalogues and entitlements to health care in Germany: Decision makers, decision criteria and taxonomy of catalogues
   Discussion Papers, Technische Universität Berlin, School of Economics and Management View citations (1)

2004

4. Bürgerversicherung: Die Wirkung von Kopfprämien auf den Arbeitsmarkt
   Discussion Papers, Technische Universität Berlin, School of Economics and Management View citations (2)

Journal Articles

2017

1. Health-economic evaluation of home telemonitoring for COPD in Germany: evidence from a large population-based cohort
   The European Journal of Health Economics, 2017, 18, (7), 869-882 View citations (1)
2. Preferred supplier contracts in post-patent prescription drug markets
   Health Care Management Science, 2017, 20, (3), 419-432 View citations (9)

2016

3. Cost-Utility Analysis of Telemonitoring Interventions for Patients with Chronic Obstructive Pulmonary Disease (COPD) in Germany
   Applied Health Economics and Health Policy, 2016, 14, (6), 691-701 View citations (1)
4. Costs and outcomes of the German disease management programme (DMP) for chronic obstructive pulmonary disease (COPD)—A large population-based cohort study
   Health Policy, 2016, 120, (9), 1029-1039 View citations (4)
5. Dispensing behaviour of pharmacies in prescription drug markets
   Health Policy, 2016, 120, (2), 190-197
6. Economic Burden and Quality-of-Life Effects of Chronic Lymphocytic Leukemia: A Systematic Review of the Literature
   PharmacoEconomics, 2016, 34, (5), 479-498 View citations (2)
7. Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia
   Health Policy, 2016, 120, (10), 1115-1122 View citations (8)
8. The diffusion of generics after patent expiry in Germany
   The European Journal of Health Economics, 2016, 17, (8), 1027-1040 View citations (5)

2014

9. Cost-Utility Analysis Comparing Heavy-Weight and Light-Weight Mesh in Laparoscopic Surgery for Unilateral Inguinal Hernias
   Applied Health Economics and Health Policy, 2014, 12, (2), 151-163
10. Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data
    The European Journal of Health Economics, 2014, 15, (2), 133-142 View citations (2)
11. MEASURING THE RELATIONSHIP BETWEEN COSTS AND OUTCOMES: THE EXAMPLE OF ACUTE MYOCARDIAL INFARCTION IN GERMAN HOSPITALS
    Health Economics, 2014, 23, (6), 653-669 View citations (8)
    See also Working Paper Measuring the relationship between costs and outcomes: The example of Acute Myocardial Infarction in German hospitals, hche Research Papers (2012) View citations (5) (2012)

2013

12. Reforms in the Greek pharmaceutical market during the financial crisis
    Health Policy, 2013, 109, (1), 1-6 View citations (17)
13. The Trade-off Between Costs and Quality of Care in the Treatment of Psychosomatic Patients with Somatoform Pain Disorder
    Applied Health Economics and Health Policy, 2013, 11, (4), 359-368 View citations (3)

2012

14. A framework to evaluate the effects of small area variations in healthcare infrastructure on diagnostics and patient outcomes of rare diseases based on administrative data
    Health Policy, 2012, 105, (2), 110-118 View citations (5)
15. Cost Effectiveness of Drug-Eluting Stents in Acute Myocardial Infarction Patients in Germany
    Applied Health Economics and Health Policy, 2012, 10, (4), 235-248 View citations (2)
16. Cost-effectiveness of open versus laparoscopic appendectomy: a multilevel approach with propensity score matching
    The European Journal of Health Economics, 2012, 13, (5), 549-560
17. Effect of Type of Insurance and Income on Waiting Time for Outpatient Care
    The Geneva Papers on Risk and Insurance - Issues and Practice, 2012, 37, (4), 609-632 View citations (12)
    See also Working Paper Effect of type of insurance and income on waiting time for outpatient care, hche Research Papers (2011) View citations (4) (2011)

2011

18. Availability of and Access to Orphan Drugs
    PharmacoEconomics, 2011, 29, (1), 63-82 View citations (2)
19. Costs and quality of hospitals in different health care systems: a multi‐level approach with propensity score matching
    Health Economics, 2011, 20, (1), 85-100 View citations (16)
20. Modelling pharmaceutical price changes in Germany: a function of competition and regulation
    Applied Economics, 2011, 43, (29), 4515-4526 View citations (10)
21. Reimbursement of pharmaceuticals: reference pricing versus health technology assessment
    The European Journal of Health Economics, 2011, 12, (3), 263-271 View citations (11)

2010

22. The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany
    The European Journal of Health Economics, 2010, 11, (3), 267-277 View citations (14)

2007

23. Pricing behaviour of pharmacies after market deregulation for OTC drugs: The case of Germany
    Health Policy, 2007, 84, (1), 30-38 View citations (6)

2006

24. Methods to determine reimbursement rates for diagnosis related groups (DRG): A comparison of nine European countries
    Health Care Management Science, 2006, 9, (3), 215-223 View citations (45)

2005

25. Defining the “Health Benefit Basket” in nine European countries
    The European Journal of Health Economics, 2005, 6, (1), 2-10 View citations (13)
26. Determining the “Health Benefit Basket” of the Statutory Health Insurance scheme in Germany
    The European Journal of Health Economics, 2005, 6, (1), 30-36 View citations (8)